ClinicalTrials.gg
CompletedNCT03993639Updated Jan 22, 2021

KRN125 for Mobilization of Hematopoietic Stem Cells

A Phase 2 interventional study of Pegfilgrastim in Peripheral Blood Stem Cell Transplantation, sponsored by Kyowa Kirin Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 20 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-01-22.

Sponsored by Kyowa Kirin Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
20 Years to 55 Years
Sex
All
01

Study summary

Data collection to evaluate safety and effect of hematopoietic stem cell mobilization into the peripheral blood after a single subcutaneous (SC) dose of KRN125(Pegfilgrastim)in healthy adults.

Read the detailed description

KRN125 is administered as a single SC dose to the Day 1. The stem cell mobilization protocols will be monitored for safety and efficacy during the mobilization period.

02

Conditions studied

  • Peripheral Blood Stem Cell Transplantation

Keywords

  • Hematopoietic Stem Cells Mobilization
  • Healthy Volunteer (HV)
  • filgrastim
  • allogenic hematopoetic stem cell transplantation
03

In context

Lead sponsor

Kyowa Kirin Co., Ltd. is the lead sponsor of 159 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Japanese subjects aged 20 to 55 years or younger at the submission of the written form
  • Women weighing 40 kg or more and 80 kg or less and men weighing 45 kg or more and 80 kg or less at the time of the preliminary examination

Exclusion criteria

Exclusion Criteria:

  • Subjects with a current medical history or who have been judged to be inappropriate for the study (e.g., significant neurological, hepatic, renal, endocrine, cardiovascular, blood, gastrointestinal, respiratory, and metabolic diseases, , myeloproliferative disorder, or psychiatric disorders)
  • Individuals with alcohol or drug dependence, or individuals who have not tested negative for all drugs of abuse in the preliminary test
  • Subjects with a history or current history of drug allergy or symptomatic allergy
  • .Active infection or history of recurrent infection- However, only patients who are HBsantibody-positive by vaccination and whose HBV-DNA is less than the lower limit of quantitation will be allowed to participate in this study.
  • Subjects who used drugs within 2 weeks before administration of the drug.
  • Subjects who have had at least 200 mL of blood drawn within 3 months before administration of the investigational drug.
  • Pregnant or lactating
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    KRN125

    Single SC administration

    Drug: Pegfilgrastim

Interventions

06

What researchers measure

Primary outcomes

  1. Achievement of >20 cells/μL positive for CD34 in peripheral blood from baseline to Day 7

    Time frame: Baseline to Day 7

Secondary outcomes

  1. • Period from baseline to first time peripheral blood CD34 positive cells >20 cells/μL

    Time frame: Baseline to Day 15 or through study completion, an average of 1 year

  2. • Time from baseline to peak peripheral blood CD34 positive cells

    Time frame: Baseline to Day 15 or through study completion, an average of 1 year

  3. • Achievement of >10 cells/μL positive for CD34 in peripheral blood from baseline to Day 7

    Time frame: Baseline to Day 7

  4. • Peripheral blood CD34 positive cell count

    Time frame: Baseline to Day 15 or through study completion, an average of 1 year

  5. • Peripheral blood white blood cell count

    Time frame: Baseline to Day 15 or through study completion, an average of 1 year

  6. • Peripheral blood neutrophil count

    Time frame: Baseline to Day 15 or through study completion, an average of 1 year

07

Study locations

1 site
  • Hokkaido University Hospital
    Sapporo, Hokkaido, Japan
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2019 to primary completion in Jul 2020, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2019
First posted
Jun 21, 2019
StartActual
May 28, 2019
Primary completionActual
Jul 21, 2020
CompletionActual
Aug 28, 2020
Last update
Jan 22, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03993639
Responsible party
Sponsor
First posted
Jun 21, 2019
Start date
May 28, 2019
Primary completion
Jul 21, 2020
Completion
Aug 28, 2020
Last update
Jan 22, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegfilgrastim

Start the discussion